Those vaccines include a shot against norovirus, a highly contagious stomach bug that causes vomiting and diarrhea; a vaccine against Epstein-Barr virus, a common herpes virus that can cause contagious infections and is associated with some cancers; and a shot designed to target a virus that causes shingles and chickenpox.
There is currently no approved shot to prevent norovirus, the most common cause of the stomach flu. The virus results in approximately 200,000 deaths per year and substantial health-care costs, according to Moderna.
The company examined two different norovirus shot candidates in a phase one trial on more than 600 patients ages 18 to 80.
An interim analysis showed that a single dose of a trivalent vaccine, called mRNA-1403, targeting three strains of norovirus triggered a strong immune response across all dose sizes. The shot also had a “clinically acceptable” safety profile.
Moderna said it is moving that shot to a phase three trial. The market for norovirus vaccines represents a $3 billion to $6 billion annual market, according to Moderna.
There are also no shots currently approved to prevent Epstein-Barr virus. It accounts for more than 90% of cases of a contagious infection known as mono, which can cause fever, sore throat, and chronic fatigue. Both the virus and mono are associated with a higher risk of certain cancers.
Moderna has been developing two shots designed to tackle multiple conditions associated with Epstein-Barr virus. That includes a shot designed to prevent mono, called mRNA-1189, which will move to a phase three study after positive early-stage trial data.
A phase one trial examined that vaccine in patients 12 to 30 years of age in the U.S. The study found that the shot caused an immune response against mono and was well tolerated across all dose sizes.
You have paroxysmal supraventricular tachycardia? I recall
when I was in China about 40 years ago, in my rotation after graduating from medical school, I was treating a patient with that condition with IV injection, extremely effective.
如果被批准最后上市的话，就摆脱了只有一个产品（Covid 疫苗）在市场的局面。 当然还需要时间。
MRNA 去年股价跌了45% ， 但是从去年11月份的低谷到现在差不多翻倍了。
Those vaccines include a shot against norovirus, a highly contagious stomach bug that causes vomiting and diarrhea; a vaccine against Epstein-Barr virus, a common herpes virus that can cause contagious infections and is associated with some cancers; and a shot designed to target a virus that causes shingles and chickenpox.
看到阿猫说过好几次他所在的实验室做的乳腺癌方面研究的东西好像有点突破，每次我都是在心里呵呵。
严格讲这三种疫苗都不是创新， 至多算得上升级版
There is currently no approved shot to prevent norovirus, the most common cause of the stomach flu. The virus results in approximately 200,000 deaths per year and substantial health-care costs, according to Moderna.
The company examined two different norovirus shot candidates in a phase one trial on more than 600 patients ages 18 to 80.
An interim analysis showed that a single dose of a trivalent vaccine, called mRNA-1403, targeting three strains of norovirus triggered a strong immune response across all dose sizes. The shot also had a “clinically acceptable” safety profile.
Moderna said it is moving that shot to a phase three trial. The market for norovirus vaccines represents a $3 billion to $6 billion annual market, according to Moderna.
There are also no shots currently approved to prevent Epstein-Barr virus. It accounts for more than 90% of cases of a contagious infection known as mono, which can cause fever, sore throat, and chronic fatigue. Both the virus and mono are associated with a higher risk of certain cancers.
Moderna has been developing two shots designed to tackle multiple conditions associated with Epstein-Barr virus. That includes a shot designed to prevent mono, called mRNA-1189, which will move to a phase three study after positive early-stage trial data.
A phase one trial examined that vaccine in patients 12 to 30 years of age in the U.S. The study found that the shot caused an immune response against mono and was well tolerated across all dose sizes.
当科技要转化为资本时， 华尔街， 媒体就要做好托儿， 这是他们的使命。
细思慎行有必要。
health would have the biggest bargaining power over other demand
when I was in China about 40 years ago, in my rotation after graduating from medical school, I was treating a patient with that condition with IV injection, extremely effective.
very fast to take effect, feeling like on a roller coaster for a few seconds, then all calm and beat normal.
I had more episodes after recovery from Covid or vaccine in high intensity excercise, like once a year. I didnot know what it was untill last Sunday.
连early stage development 都算不上。他不知道还需要多少resource才能完成从他这里出去的成功的candidate，所以他一直狠乐观。我经过多了2期数据很好，三期却完全失败的案例，比较悲观。因为绝大部分在实验室数据好的，最后都是以失败告终的。
很多药物的起始阶段都靠实验室的研究，mRNA疫苗十年前有多少人看中呢。。。说我缺乏勇气的，其实是不懂我take的risk...
如果从投资角度看，我这一博的回报还算不错。60岁就进入可退可不退的阶段。如果健康容许，我可能陪老板一起老去。。。前15年很辛苦，后10年很轻松，还可能一直玩下去。。。但我知道，大多我这样的博士后没有这样的运气，不仅仅是药物筛选上走这么远，更可能饭碗中间就丢了。
从没为自己的选择后悔。你让我把leads转给你们公司，我不敢，也没这个权利，所以，我不回你。你是我校友，在家坛的时候就知道。母校出来的，我们生物系的，有志向的人很多。我同班不同专业的同学就有搞成功，卖给大公司后发财了，去加州买葡萄园的，他的酒我喝了好几瓶了。他不仅自己发财，还捐赠给母校帮助贫困生，现在有出山办药物公司。。。